RNA-based Therapeutics Market Size, Share, Growth and Forecast, 2025-2035

Gene silencing and mRNA medicines reach wider use

The global RNA-based therapeutics market was valued at USD 9.90 billion in 2025 and is projected to increase from USD 11.03 billion in 2026 to USD 29.28 billion by 2035, registering a CAGR of 11.45% during 2026–2035. Demand comes from small interfering RNA and antisense medicines for rare inherited disorders, heart disease and blood disorders, together with messenger RNA vaccines for respiratory infections. North America held the largest regional share, 48.0% in 2025, because most approved products launched first in the United States and carry high specialty prices there. Asia Pacific is the fastest-growing region at 12.77% a year, as China, Japan and South Korea expand local development and manufacturing. The commercial picture changed in March 2025, when the FDA approved the first siRNA medicine for hemophilia, dosed only once every two months. As a result, gene silencing moved further into common chronic conditions with large treated populations.

Which RNA medicines and vaccines does this analysis cover?

The analysis counts approved medicines and vaccines whose active ingredient is RNA or a synthetic strand that binds RNA, including small interfering RNA, antisense oligonucleotides, messenger RNA vaccines and related designs. Values are based on manufacturer selling prices for products bought by hospitals, specialty centers and research institutes.

Small molecules that target RNA, laboratory reagents, extraction kits and contract synthesis services sit outside the scope of this analysis. The value chain runs from platform developers and nucleotide suppliers through fill and finish plants to specialty distributors, hospital pharmacies and vaccination programs that reach patients.

Drugs lead as RNA interference gains the fastest

Why do drugs lead over vaccines in RNA medicine spending?

Based on product, the market is categorized into vaccines and drugs. Drugs led with a 62.0% share of 2025 value, because siRNA and antisense medicines for rare conditions carry high annual prices per patient. Drugs also grow fastest at 11.93% a year, as new labels add heart and blood disorders. Vaccine demand stabilized after the pandemic peak, yet newer messenger RNA vaccines for RSV and COVID-19 keep a sizable seasonal base.

Why does RNA interference grow fastest among types?

Based on type, the market is categorized into RNA interference, RNA antisense and other designs, which include messenger RNA. RNA Interference led with a 40.0% share of 2025 value and also grows fastest at 12.04% a year, because liver-targeted siRNA medicines need only two to six doses each year. Antisense medicines keep a strong position in neuromuscular and lipid disorders, while messenger RNA sits mainly in respiratory vaccines.

Why do rare genetic diseases grow fastest among indications?

Based on indication, the market is categorized into infectious diseases, rare genetic diseases and other conditions. Infectious Diseases led with a 40.0% share of 2025 value, because messenger RNA vaccines for COVID-19 and RSV still reach millions of adults each season. Rare Genetic Diseases grow fastest at 12.26% a year, as new approvals cover inherited lipid, blood, swelling and amyloid disorders that had few treatment options.

Why do specialty centers grow fastest among end users?

Based on end use, the market is categorized into hospital, specialty centers and research institutes. Hospital settings led with a 55.0% share of 2025 value, because infusions, first doses and many vaccinations happen there. Specialty Centers grow fastest at 11.95% a year, as hemophilia, amyloidosis and angioedema clinics manage long-term siRNA and antisense patients. Research institutes buy smaller volumes mainly for use in clinical studies.

Rare disease need and long dosing gaps lift demand

How does unmet need in rare disease lift demand for gene silencing?

Unmet need in rare disease lifts demand for gene silencing, because RNA medicines can switch off a faulty gene product directly. The U.S. National Center for Advancing Translational Sciences counts about 10,000 known rare diseases affecting an estimated 25 million to 30 million people in the United States. The agency also notes that only about 5% of rare diseases have an FDA-approved treatment. In December 2024, Ionis received FDA approval for Tryngolza as the first treatment for adults with familial chylomicronemia syndrome. As a result, rare genetic diseases grow fastest among indications at 12.26% a year, as each new label reaches patients who previously had no approved medicine and stay on treatment for many years.

Why do long dosing intervals widen use of siRNA medicines?

Long dosing intervals widen use of siRNA medicines, because patients can replace frequent infusions with a few injections each year. In March 2025, Alnylam announced FDA approval of Qfitlia for hemophilia A or B, given once every two months in patients 12 years and older. Qfitlia was described as the first siRNA medicine approved for hemophilia, and Sanofi holds global commercial rights. In November 2025, Arrowhead received FDA approval for Redemplo, an siRNA medicine given once every three months for familial chylomicronemia syndrome. In turn, RNA interference grows fastest among types at 12.04% a year, while established hemophilia care faces a new low-frequency option for patients with or without inhibitors.

Download Free Sample

How do new mRNA vaccine approvals sustain the vaccine base?

New messenger RNA vaccine approvals sustain the vaccine base, because the platform now covers more than one respiratory virus. On May 31, 2024, the FDA approved Moderna mRESVIA for RSV in adults aged 60 and older, the first messenger RNA vaccine for a disease other than COVID-19. In May 2025, Moderna received FDA approval for mNEXSPIKE, its third approved product. However, the Centers for Disease Control and Prevention estimated that 38.5% of adults aged 65 and older had received a 2024 to 2025 COVID-19 vaccine by early November 2024. As a result, vaccines keep a large seasonal base among older adults, while yearly uptake and new respiratory labels set the pace of vaccine demand.

Why are large acquisitions funding RNA pipelines?

Large acquisitions are funding RNA pipelines, because big drugmakers want proven delivery platforms rather than single products. On Feb. 27, 2026, Novartis completed its acquisition of Avidity Biosciences at USD 72.00 per share, valuing the company at about USD 12 billion. In November 2024, Sarepta licensed seven siRNA programs from Arrowhead, paying USD 500 million upfront plus a USD 325 million equity investment. In December 2025, BioNTech closed its acquisition of CureVac to strengthen messenger RNA design, delivery and manufacturing. In turn, well-funded owners can run larger trials, which lifts the number of late-stage programs aimed at muscle, brain and lung diseases through 2035.

Heart disease labels and in vivo cell therapy emerge

How is gene silencing shifting toward heart disease?

Gene silencing is shifting toward heart disease, because cardiac patient groups are far larger than classic rare disorders. On March 20, 2025, Alnylam received FDA approval for Amvuttra to reduce cardiovascular death, hospital visits and urgent heart failure visits in adults with transthyretin amyloidosis cardiomyopathy. In December 2024, Tryngolza became the first approved treatment for familial chylomicronemia syndrome, a severe lipid disorder. In November 2025, Redemplo joined it as a quarterly siRNA option, and Arrowhead estimates about 6,500 people in the United States have the condition. As a result, cardiometabolic labels are becoming a core source of growth for drugs, as each label adds patients who need lifelong treatment.

Why is in vivo cell therapy emerging on circular RNA?

In vivo cell therapy is emerging on circular RNA, because the approach lets a patient's body make engineered immune cells without outside processing. On Feb. 9, 2026, Lilly agreed to acquire Orna Therapeutics in a deal valued at up to USD 2.4 billion, including milestone payments. Orna pairs engineered circular RNA with lipid nanoparticles, and its lead program ORN-252 is a CD19-targeting in vivo CAR-T candidate. Lilly plans to test ORN-252 in autoimmune diseases driven by B cells. BioNTech also cited mRNA cancer immunotherapy as a reason for buying CureVac in 2025. In turn, other designs, including messenger and circular RNA, are moving from vaccines into immune and cancer treatment.

Download Free Sample

Can muscle-targeted conjugates open neuromuscular demand?

Developers have a clear opening in neuromuscular disease, because conjugates can carry RNA medicines into muscle tissue rather than only the liver. Novartis said the Avidity deal added three late-stage programs for genetic neuromuscular diseases built on antibody oligonucleotide conjugates. Sarepta licensed Arrowhead programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1 in November 2024. That deal also covers spinocerebellar ataxias, Huntington's disease and idiopathic pulmonary fibrosis, which widens targets beyond muscle. Better delivery also lifts demand for oligonucleotide synthesis capacity at contract plants. As a result, muscle and brain programs are expected to add new late-stage candidates for inherited diseases through 2035.

Where can prophylactic RNA medicines add new value?

Prophylactic RNA medicines can add new value in swelling and bleeding disorders, because steady prevention replaces emergency treatment. In August 2025, Ionis received FDA approval for Dawnzera to prevent attacks of hereditary angioedema in patients aged 12 and older. In its trial, Dawnzera cut monthly attacks by 81% versus placebo over 24 weeks, with dosing every four or eight weeks. The condition affects roughly 1 in 50,000 people worldwide and drives 15,000 to 30,000 U.S. hospital visits each year. In turn, specialty centers that manage chronic prophylaxis grow fastest among end users at 11.95% a year, as patients move to longer intervals.

Delivery limits, costs and vaccine fatigue slow uptake

Why do delivery limits keep many targets out of reach?

Delivery limits keep many targets out of reach, because most approved siRNA medicines rely on liver uptake. Reaching muscle, brain, lung and tumor tissue needs new conjugates or lipid carriers that are still in trials. Each new delivery method also needs its own safety data and manufacturing process before regulators accept it. As a result, many diseases with clear genetic causes remain without an RNA option, even as acquisitions fund work on delivery beyond the liver. Developers that solve tissue reach first will gain a long lead in brain and muscle disorders.

How do high prices limit access outside the United States?

High prices limit access outside the United States, because rare disease medicines often cost hundreds of thousands of dollars each year. European health technology reviews often take a year or more before national coverage begins. Payers in Asia and Latin America cover few of these products, and many patients pay out of pocket or go untreated. In turn, value stays concentrated in North America, while companies test outcome-based contracts, tiered pricing and managed access programs to widen reach in other regions.

Why does lower vaccine uptake weigh on messenger RNA sales?

Lower vaccine uptake weighs on messenger RNA sales, because seasonal COVID-19 vaccination has fallen sharply since 2021. Narrower U.S. eligibility rules for COVID-19 vaccines in 2025 also limited the population covered by default. Public trust in new vaccine technologies also varies widely between countries and age groups. As a result, vaccine makers depend on new respiratory, combination and cancer programs to replace lost volume, while governments buy smaller seasonal orders than in earlier years.

How do manufacturing and patent complexity raise costs?

Manufacturing and patent complexity raise costs, because RNA medicines need specialized synthesis, purification and cold chain handling. Lipid nanoparticle and modified nucleotide patents have led to long legal disputes between developers. Smaller companies must license several delivery and chemistry technologies before a product can launch. In turn, newcomers face higher entry costs and longer timelines, which favors large platform owners with in-house plants, broad patent estates and experienced regulatory teams.

North America leads as Asia Pacific gains pace

Why do early U.S. launches keep North America in the lead?

North America held 48.0% of 2025 value and grows at 11.07% a year through 2035. The United States drives this position, because Qfitlia, Amvuttra for cardiomyopathy, Tryngolza, Dawnzera and Redemplo all received FDA approval between December 2024 and November 2025. Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Moderna, Inc. and Sarepta Therapeutics, Inc. are based in the country. Specialty pricing and commercial insurance support high spending per treated patient.

How does Europe balance platform strength with price control?

Europe held 26.0% of 2025 value and grows at 10.97% a year through 2035. Novartis AG and Sanofi are based in the region, and BioNTech completed its acquisition of Curevac SE in Germany in December 2025. However, health technology reviews and national price negotiations delay coverage for many rare disease medicines. This keeps regional growth below the global average despite strong research capacity.

Download Free Sample

Why do China and Japan drive Asia Pacific growth?

Asia Pacific held 18.0% of 2025 value and is the fastest-growing region at 12.77% a year. China and Japan are building local siRNA and messenger RNA capacity, and Sirnaomics develops RNA interference candidates from the region. Large patient populations with lipid, liver and viral diseases offer room for new labels. Wider insurance coverage for rare disease medicines also supports demand.

Why are vaccination programs central in Latin America?

Latin America held 4.5% of 2025 value and grows at 12.07% a year through 2035. Brazil and Mexico lead regional spending, where public vaccination programs account for much of the messenger RNA volume. Access to rare disease medicines depends on court orders and public tenders in several countries.

Why does access remain uneven across the Middle East and Africa?

The Middle East and Africa held 3.5% of 2025 value and grows at 12.17% a year through 2035. Gulf states fund specialist centers and genetic screening, while much of Africa relies on donor vaccination programs. This gap limits access to siRNA and antisense medicines outside major cities.

Download Free Sample

Approvals and deals in gene silencing since 2024

Conjugates, lipid carriers and circular designs advance

• Liver-targeted conjugates attach sugar groups to siRNA strands, which allows dosing every two to six months under the skin.
• Antibody oligonucleotide conjugates link RNA strands to antibodies, which carries the medicine into muscle tissue.
• Lipid nanoparticles protect messenger and circular RNA during delivery, which supports vaccines and in vivo cell therapy.
• Circular RNA designs lack free ends that enzymes attack, which can extend protein production inside cells.
• Modified nucleotides reduce unwanted immune reactions, which improves tolerability for repeated doses.

Platform owners compete on delivery and dosing gaps

Competition is led by platform owners that control both chemistry and delivery. Alnylam Pharmaceuticals, Inc. leads RNA interference with several approved liver-targeted medicines, while Ionis Pharmaceuticals, Inc. leads antisense medicines for lipid, swelling and neurological disorders. Moderna, Inc. and Pfizer, Inc. compete in messenger RNA vaccines, and BioNTech added Curevac SE in December 2025. Novartis AG, Sanofi and Sarepta Therapeutics, Inc. combine licensing and acquisitions with their own specialty sales networks. Orna Therapeutics brings circular RNA under Lilly ownership, while Sirnaomics develops RNA interference candidates in Asia. Partnerships remain common, because smaller developers license programs to companies with global sales forces and payer experience. As a result, companies compete on dosing intervals, tissue reach beyond the liver, outcome data in larger diseases, patent strength and manufacturing scale, and each new heart or muscle label tests how well a platform performs in broader patient groups.

Companies profiled and their roles in this market

Gene silencing drugs set the pace to 2035

Credence Research's view is that gene silencing drugs will set the pace of growth through 2035, because each new siRNA or antisense label reaches patients who stay on treatment for years. The overall market grows at 11.45% a year, supported by rare disease approvals, heart disease labels and long dosing intervals. Vaccines keep a meaningful seasonal base, yet drugs gain share every year. Companies that move RNA medicines beyond the liver into muscle and brain tissue will win the most new value.

How Credence Research sized RNA medicine spending

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by product, type, indication, end use and region. Regional and segment splits are Credence Research estimates informed by U.S. government statistics, FDA decisions and company press releases and regulatory filings. No primary interviews or surveys were used in preparing this edition of the report.

RNA medicine outlook to 2035

By 2035, the RNA-based therapeutics market is projected to reach USD 29.28 billion, with growth led by siRNA and antisense medicines for rare, lipid and heart disorders. Drugs will widen their lead over vaccines, as quarterly and twice-yearly dosing reaches larger patient groups. North America keeps the highest spending per patient, while Asia Pacific adds the most new capacity. Circular RNA and muscle-targeted conjugates will open new disease areas. As a result, advantage will depend on delivery reach, outcome data and manufacturing scale.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.